Matches in SemOpenAlex for { <https://semopenalex.org/work/W2056516640> ?p ?o ?g. }
Showing items 1 to 86 of
86
with 100 items per page.
- W2056516640 endingPage "54" @default.
- W2056516640 startingPage "49" @default.
- W2056516640 abstract "This paper presents a summary of the evidence review group (ERG) report into the clinical effectiveness and cost-effectiveness of cetuximab for recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) based upon a review of the manufacturer’s submission to the National Institute for Health and Clinical Excellence (NICE) as part of the single technology appraisal (STA) process. The submission’s evidence came from a single reasonably high-quality randomised controlled trial (RCT) [EXTREME (Erbitux in First-Line Treatment of Recurrent or Metastatic Head and Neck Cancer); n = 442] comparing cetuximab plus chemotherapy (CTX) with CTX alone. Cetuximab plus CTX had significant effects compared with CTX alone on the primary outcome of overall survival (10.1 versus 7.4 months respectively) and the secondary outcomes of progression-free survival (PFS) (5.6 versus 3.3 months), best overall response to therapy (35.6% versus 19.5%), disease control rate (81.1% versus 60%) and time-totreatment failure (4.8 versus 3.0 months), but not on duration of response (5.6 months versus 4.7 months). No safety issues with cetuximab arose beyond those already previously documented. The manufacturer developed a two-arm state-transition Markov model to evaluate the cost-effectiveness of cetuximab plus CTX versus CTX alone, using clinical data from the EXTREME trial. The ERG recalculated the base-case cost-effectiveness results taking changes in parameters and assumptions into account. Subgroup and threshold analyses were also explored. The manufacturer reported an incremental cost-effectiveness ratio (ICER) of £121,367 per quality-adjusted life-year (QALY) gained and an incremental cost per life-year gained of £92,226. Univariate sensitivity analysis showed that varying the cost of day-case infusion and the utility values in the stable/response health state of the cetuximab plus CTX arm had the greatest impact on the ICER. Probabilistic sensitivity analysis illustrated that cetuximab plus CTX is unlikely to be cost-effective for patients with recurrent and/or metastatic SCCHN, even at what would usually be considered very high levels of willingness to pay for an additional QALY. With regard to the economic model the appropriateness and reliability of parametric survival projection beyond the duration of trial data could not be fully explored because of lack of information. The ERG also questioned the appropriateness of economic modelling in this STA as evidence is available only from a single RCT. In conclusion, the ERG considers that patients with metastatic SCCHN were not shown to receive a significant survival benefit from cetuximab plus CTX compared with CTX alone and that even setting a lower price for cetuximab would not strengthen the manufacturer’s case for cost-effectiveness." @default.
- W2056516640 created "2016-06-24" @default.
- W2056516640 creator A5011624664 @default.
- W2056516640 creator A5030009531 @default.
- W2056516640 creator A5033000612 @default.
- W2056516640 creator A5041932491 @default.
- W2056516640 creator A5049004669 @default.
- W2056516640 creator A5058647212 @default.
- W2056516640 creator A5068763092 @default.
- W2056516640 creator A5084858270 @default.
- W2056516640 date "2009-10-01" @default.
- W2056516640 modified "2023-09-27" @default.
- W2056516640 title "Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck" @default.
- W2056516640 cites W1593173821 @default.
- W2056516640 doi "https://doi.org/10.3310/hta13suppl3/08" @default.
- W2056516640 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19846029" @default.
- W2056516640 hasPublicationYear "2009" @default.
- W2056516640 type Work @default.
- W2056516640 sameAs 2056516640 @default.
- W2056516640 citedByCount "35" @default.
- W2056516640 countsByYear W20565166402012 @default.
- W2056516640 countsByYear W20565166402013 @default.
- W2056516640 countsByYear W20565166402014 @default.
- W2056516640 countsByYear W20565166402015 @default.
- W2056516640 countsByYear W20565166402016 @default.
- W2056516640 countsByYear W20565166402022 @default.
- W2056516640 crossrefType "journal-article" @default.
- W2056516640 hasAuthorship W2056516640A5011624664 @default.
- W2056516640 hasAuthorship W2056516640A5030009531 @default.
- W2056516640 hasAuthorship W2056516640A5033000612 @default.
- W2056516640 hasAuthorship W2056516640A5041932491 @default.
- W2056516640 hasAuthorship W2056516640A5049004669 @default.
- W2056516640 hasAuthorship W2056516640A5058647212 @default.
- W2056516640 hasAuthorship W2056516640A5068763092 @default.
- W2056516640 hasAuthorship W2056516640A5084858270 @default.
- W2056516640 hasBestOaLocation W20565166401 @default.
- W2056516640 hasConcept C112930515 @default.
- W2056516640 hasConcept C121608353 @default.
- W2056516640 hasConcept C126322002 @default.
- W2056516640 hasConcept C141071460 @default.
- W2056516640 hasConcept C143998085 @default.
- W2056516640 hasConcept C168563851 @default.
- W2056516640 hasConcept C2776530083 @default.
- W2056516640 hasConcept C2776833033 @default.
- W2056516640 hasConcept C2779998722 @default.
- W2056516640 hasConcept C3019080777 @default.
- W2056516640 hasConcept C526805850 @default.
- W2056516640 hasConcept C535046627 @default.
- W2056516640 hasConcept C71924100 @default.
- W2056516640 hasConceptScore W2056516640C112930515 @default.
- W2056516640 hasConceptScore W2056516640C121608353 @default.
- W2056516640 hasConceptScore W2056516640C126322002 @default.
- W2056516640 hasConceptScore W2056516640C141071460 @default.
- W2056516640 hasConceptScore W2056516640C143998085 @default.
- W2056516640 hasConceptScore W2056516640C168563851 @default.
- W2056516640 hasConceptScore W2056516640C2776530083 @default.
- W2056516640 hasConceptScore W2056516640C2776833033 @default.
- W2056516640 hasConceptScore W2056516640C2779998722 @default.
- W2056516640 hasConceptScore W2056516640C3019080777 @default.
- W2056516640 hasConceptScore W2056516640C526805850 @default.
- W2056516640 hasConceptScore W2056516640C535046627 @default.
- W2056516640 hasConceptScore W2056516640C71924100 @default.
- W2056516640 hasFunder F4320334661 @default.
- W2056516640 hasIssue "Suppl 3" @default.
- W2056516640 hasLocation W20565166401 @default.
- W2056516640 hasLocation W20565166402 @default.
- W2056516640 hasLocation W20565166403 @default.
- W2056516640 hasOpenAccess W2056516640 @default.
- W2056516640 hasPrimaryLocation W20565166401 @default.
- W2056516640 hasRelatedWork W1956415942 @default.
- W2056516640 hasRelatedWork W1996158748 @default.
- W2056516640 hasRelatedWork W2047962734 @default.
- W2056516640 hasRelatedWork W2059609278 @default.
- W2056516640 hasRelatedWork W2062707457 @default.
- W2056516640 hasRelatedWork W2077763859 @default.
- W2056516640 hasRelatedWork W2081836551 @default.
- W2056516640 hasRelatedWork W3012537123 @default.
- W2056516640 hasRelatedWork W3093167374 @default.
- W2056516640 hasRelatedWork W3154194420 @default.
- W2056516640 hasVolume "13" @default.
- W2056516640 isParatext "false" @default.
- W2056516640 isRetracted "false" @default.
- W2056516640 magId "2056516640" @default.
- W2056516640 workType "article" @default.